CP and COVID-19: Considering the complexity of COVID‐19 (including SARS‐CoV‐2 infection and long COVID) and patient heterogeneity, administration of SARS‐CoV‐2‐targeting blood‐derived products (COVID‐19 CP, COVID‐HIG, and neutralizing IgG) and non‐SARS‐CoV‐2‐targeting blood‐derived products (IVIG and albumin) should be carefully timed and dosed to achieve the most efficient COVID‐19 treatment outcomes.